DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

236 Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of
antimuscarinic treatments in overactive bladder: a systematic
review and meta-analysis. Eur Urol, 2005, 48:5–26.
Chapple RR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind
placebo- and tolterodine-controlled trial of the oncedaily
antimuscarinic agent solifenacin in patients with
symptomatic overactive bladder. BJU Int, 2004, 93:303–310.
Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators
of GPCRs: A novel approach for the treatment of CNS disorders.
Nature Rev Drug Discov, 2009a, 8:41–54.
Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric
modulators of muscarinic receptors for the treatment of CNS
disorders. Trends Pharmacol Sci, 2009b, 30:148–155.
Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine
and exercise challenge testing–1999. Am J Respir Crit
Care Med, 2000, 161:309–329.
Cusack B, Nelson A, Richelson E. Binding of antidepressants to
human brain receptors: focus on newer generation compounds.
Psychopharmacology (Berl), 1994, 114:559–565.
DiFrancesco D, Tromba C. Acetylcholine inhibits activation of
the cardiac hyperpolarizing-activated current, i f
. Pflugers Arch,
1987, 410:139–142.
Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva):
mechanistical considerations and clinical profile in obstructive
lung disease. Life Sci, 1999, 64:457–464.
Eglen RM, Hegde SS, Watson, N. Muscarinic receptor subtypes
and smooth muscle function. Pharmacol Rev, 1996, 48:531–565.
Feigl EO. Neural control of coronary blood flow. J Vasc Res,
1998, 35:85–92.
Fisher JT, Vincent SG, Gomeza, J, et al. Loss of vagally mediated
bradycardia and bronchoconstriction in mice lacking M 2
or M 3
muscarinic acetylcholine receptors. FASEB J, 2004,
18:711–713.
Furchgott RF. Endothelium-derived relaxing factor: Discovery,
early studies, and identification as nitric oxide. Biosci Rep,
1999, 19:235–251.
Gautam D, Heard TS, Cui Y, et al. Cholinergic stimulation of
salivary secretion studied with M 1
and M 3
muscarinic receptor
single- and double-knockout mice. Mol Pharmacol, 2004,
66:260–267.
Goessl C, Sauter T, Michael T, et al. Efficacy and tolerability of
tolterodine in children with detrusor hyperreflexia. Urology,
2000, 55:414–418.
Goldfrank LR. Mushrooms. In, Goldfrank’s Toxicologic
Emergencies, 8th ed. (Flomenbaum NE, Goldfrank LR,
Hoffman RS, et al., eds.) McGraw-Hill, New York, 2006,
pp. 1564–1576.
Gomeza J, Shannon H, Kostenis E, et al. Pronounced pharmacologic
deficits in M 2
muscarinic acetylcholine receptor knockout
mice. Proc Natl Acad Sci USA, 1999, 96:1692–1697.
Goyal RK, Rattan S. Neurohumoral, hormonal, and drug receptors
for the lower esophageal sphincter. Gastroenterology,
1978, 74:598–619.
Gross NJ. Tiotropium bromide. Chest, 2004, 126:1946–1953.
Hamilton SE, Loose MD, Qi M, et al. Disruption of the M 1
receptor gene ablates muscarinic receptor-dependent M current
regulation and seizure activity in mice. Proc Natl Acad
Sci USA, 1997, 94:13311–13316.
Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating
smooth muscle contractility in the urinary bladder. Life Sci,
1999, 64:419–428.
SECTION II
NEUROPHARMACOLOGY
Hulme EC, Lu ZL, Bee MS. Scanning mutagenesis studies of
the M 1
muscarinic acetylcholine receptor. Recept Chann,
2003, 9:215–228.
Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling
molecule in the vascular system: An overview. J
Cardiovasc Pharmacol, 1999, 34:879–886.
Kay G, Crook, T, Rekeda L, et al. Differential effects of the
antimuscarinic agents darifenacin and oxybutynin ER on
memory in older subjects. Eur Urol, 2006, 50:317–326.
Kent KM, Epstein SE. Neural basis for the genesis and control
of arrhythmias associated with myocardial infarction.
Cardiology, 1976, 61:61–74.
Kent KM, Epstein SE, Cooper T, Jacobowitz DM. Cholinergic
innervation of the canine and human ventricular conducting
system. Anatomic and electrophysiologic correlations.
Circulation, 1974, 50:948–955.
Khurana S, Chacon I, Xie G, et al. Vasodilatory effects of cholinergic
agonists are greatly dimished in aorta from M 3
R –/– mice.
Eur J Pharmacol, 2004, 493:127–132.
Köppel C. Clinical sympatomatology and management of mushroom
poisoning. Toxicon, 1993, 31:1513–1540.
Krnjevíc K. Synaptic mechanisms modulated by acetylcholine
in cerebral cortex. Prog Brain Res, 2004, 145:81–93.
Lakatta EG, DiFrancesco D. What keeps us ticking: a funny current,
a calcium clock, or both? J Mol Cell Cardiol, 2009,
47:157–170.
Lamping KG, Wess J, Cui Y, et al. Muscarinic (M) receptors in
coronary circulation. Arterioscler Thromb Vasc Biol, 2004,
24:1253–1258.
Levy MN, Schwartz PJ, eds. Vagal Control of the Heart:
Experimental Basis and Clinical Implications. Futura,
Armonk, NY, 1994.
Lewis ME, Al-Khalidi AH, Bonser RS, et al. Vagus nerve stimulation
decreases left ventricular contractility in vivo in the
human and pig heart. J Physiol, 2001, 534:547–552.
Lyashkov AE, Vinogradova TM, Zahanich I, et al. Cholinergic
receptor signaling modulates spotaneous firing of sinoatrial
nodal cells via integrated effects on PKAH-dependent
Ca 2+ cycling and I KACh
. Am J Physiol, 2009, 297:949-959.
Matsui M, Motomura D, Fujikawa T, et al. Mice lacking M 2
and
M 3
muscarinic acetylcholine receptors are devoid of cholinergic
smooth muscle contractions but still viable. J Neurosci,
2002, 22:10627–10632.
Matsui M, Motomura D, Karasawa H, et al. Multiple functional
defects in peripheral autonomic organs in mice lacking muscarinic
acetylcholine receptor gene for the M 3
subtype. Proc
Natl Acad Sci USA, 2000, 97:9579–9584.
May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation
of G protein-coupled receptors. Annu Rev Pharmacol
Toxicol, 2007, 47:1–51.
Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic
potential of muscarinic receptor subtype selective agonists.
CNS Drug Rev, 2003, 9:159–186.
Moncada S, Higgs EA. Molecular mechanisms and therapeutic
strategies related to nitric oxide. FASEB J, 1995, 9:
1319–1330.
Nawaratne V, Leach K, Suratman N, et al. New insights into the
function of M 4
muscarinic acetylcholine receptors gained
using a novel allosteric modulator and a DREADD (Designer
Receptor Exclusively Activated by a Designer Drug). Mol
Pharmacol, 2008, 74:1119–1131.